Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleCannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Author(s)Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D.
Journal, Volume, IssueTranslational Psychiatry (2012) 2, e94; doi:10.1038/tp.2012.15 Published online 20 March 2012
Major outcome(s)CBD was as effective as amisulpride, a standard antipsychotic
IndicationPsychosis/schizophreniaAbstract
MedicationCannabidiol

Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermore, enhanced anandamide signaling let to a lower transition rate from initial prodromal states into frank psychosis as well as postponed transition. In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. Either treatment was safe and led to significant clinical improvement, but cannabidiol displayed a markedly superior side-effect profile. Moreover, cannabidiol treatment was accompanied by a significant increase in serum anandamide levels, which was significantly associated with clinical improvement. The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.

Route(s)Oral
Dose(s)800 mg
Duration (days)28
Participants42 patients with acute schizophrenia
DesignControlled study
Type of publicationMedical journal
Address of author(s)Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
Full texthttp://www.nature.com/tp/journal/v2/n3/full/tp201215a.html

[Back to Overview]  [IACM Homepage]


up